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Subsets of patients with non-small cell lung cancer respond remarkably well to small molecule tyrosine kinase inhibitors (TKI) specific
for epidermal growth factor receptor (EGFR) such as gefitinib or erlotinib. In 2004, it was found that EGFR mutations occurring in the
kinase domain are strongly associated with EGFR-TKI sensitivity. However, subsequent studies revealed that this relationship was not
perfect and various predictive markers have been reported. These include EGFR gene copy numbers, status of ligands for EGFR,
changes in other HER family genes or molecules downstream to EGFR including KRAS or AKT. In this review, we would like to review
current knowledge of predictive factors for EGFR-TKI. As all but one phase III trials failed to show a survival advantage of the
treatment arm involving EGFR-TKIs, it is necessary to select patients by these biomarkers in future clinical trials. Through these efforts,
it would be possible to individualise EGFR-TKI treatment for patients suffering from lung cancer.
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Lung cancer is the leading cause of cancer-related mortality in
Japan as well as in Western countries. The high mortality is mainly
because of early development of systemic disease and resistance to
currently available treatment strategies. Although various chemo-
therapeutic agents were developed in the late 1980s and 1990s,
platinum doublet therapy seems to reach a therapeutic plateau
with an objective response rate of 30–40% and a median survival
time (MST) of 8–10 months for patients with stage IIIB or IV
disease.
To circumvent this situation, a new class of drugs that
specifically targets certain molecular pathways leading to cancer
phenotypes is being actively developed. The epidermal growth
factor receptor (EGFR) pathways have been investigated as a
potential target for cancer therapy because EGFR overexpression
is frequently observed and associated with a poor prognosis or
resistance to chemotherapy. Antibodies directed against the
extracellular domain of EGFR (such as cetuximab, matuzumab
and panitumab) and small-molecule tyrosine kinase inhibitors
(TKIs) that target the kinase domain (such as gefitinib and
erlotinib) are in clinical use or in a late developmental stage.
In the phase II trail of gefitinib and early clinical development,
subgroups of patients who are of Asian origin, female sex,
adenocarcinoma and no history of smoking have been significantly
associated with a favourable response to TKIs (Fukuoka et al, 2003;
Kris et al, 2003; Miller et al, 2004). An analysis of 1974 patients
taken from the literature (Mitsudomi et al, 2006) indicated that the
TKI response is significantly dependent on ethnicity (Caucasian
10% vs East Asians 33%), gender (male 13% vs female 33%),
smoking history (never smoker 40% vs current/former smokers
11%), and histologic type (adenocarcinoma 29% vs nonadeno-
carcinoma 5%). However, it was not possible to predict gefitinib
sensitivity by levels of EGFR overexpression, determined by
immunohistochemistry or immunoblotting. The factors that
determine gefitinib sensitivity have long been an enigma.
EGFR MUTATIONS
In 2004, it was found that a subset of pulmonary adenocarcinoma
has somatic, activating mutations of the EGFR gene (Lynch et al,
2004; Paez et al, 2004; Pao et al, 2004). Following these initial
reports, various groups confirmed and extended the findings that
EGFR mutations are found in the first four exons of the tyrosine
kinase (TK) domain of the EGFR gene and about 90% of these
EGFR mutations are either short, in-frame deletions in exon 19 or
point mutations that result in a substitution of arginine for leucine
at amino acid 858 (L858R). EGFR mutations were predominantly
found in female subjects, nonsmokers, adenocarcinomas, and
Japanese patients (for review, see Mitsudomi et al, 2006). These
patient characteristics precisely coincide with those with a high
response rate to EGFR-TKIs described above. Of particular
interest, EGFR mutation is the first molecular abnormality that is
more frequent in nonsmoking patients with non-small cell lung
cancer (NSCLC). However, this does not necessarily mean that
smoking has a protective effect for EGFR mutations. Our case–
control study revealed that lung cancers harbouring EGFR
mutation appear to occur independent of tobacco smoking,
whereas lung cancers without EGFR mutations are very much
dependent on smoking dose (Matsuo et al, 2007). Apparent inverse
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www.bjcancer.comrelationship between smoking and EGFR mutations was thus
due to dilutional effect of EGFR-mutated tumours by EGFR
nonmutated tumours (Matsuo et al, 2007).
When EGFR mutations were first reported, the most exciting
finding was that lung cancer harbouring this genetic alteration
showed a striking response to EGFR-TKIs (Lynch et al, 2004; Paez
et al, 2004; Pao et al, 2004). According to the data for 1170 patients,
more than 70% of NSCLCs with EGFR mutations respond to
EGFR-TKIs, whereas 10% of tumours without EGFR mutations do
so (Table 1). Furthermore, several investigators have reported that
patients with EGFR mutations have a significantly longer survival
than those with wild-type EGFR when treated with EGFR-TKIs
(Table 1). However, data on predictors for survival are con-
troversial. Some investigators claim that EGFR mutations are
prognostic rather than predictive, because subset analysis of
TRIBUTE or INTACT trials (comparing platinum chemotherapy
with chemotherapy plus EGFR-TKI) indicated that patients with
lung cancer having EGFR mutations did better even in patients
treated only with chemotherapy (Bell et al, 2005; Eberhard et al,
2005). However, EGFR mutations was not a significant prognostic
factor in an initial two large retrospective studies in surgically
treated patients without gefitinib treatment (Kosaka et al, 2004;
Shigematsu et al, 2005), although Shigematsu et al (2005) reported
that patients with exon 19 deletion have significantly shorter
survival than those with L858R, but this is not confirmed by other
investigators so far. These results clearly show that EGFR
mutations are important in determining EGFR-TKI sensitivity,
although not perfect. High response rate in patients with EGFR
mutations to gefitinib was confirmed in the recently published
prospective phase II study (Inoue et al, 2006 and Table 1).
We first reported that response rate of gefitinib is higher for
patients with deletional EGFR mutations than for those with other
types of mutations, predominantly L858R (Mitsudomi et al, 2005)
and others extended this observation by demonstrating survival
difference between them (Jackman et al, 2006; Riely et al, 2006).
On the other hand, one of the insertion mutation (D770insNPG) in
exon 20 of the EGFR gene has been shown to be associated with
in vitro resistance to erlotinib (Greulich et al, 2005). In this study,
G719S of exon 18 showed intermediate sensitivity, suggesting the
mutation-specific treatment strategy for patient care.
Two groups of researchers have recently developed transgenic
mice that express either exon 19 deletion mutant or the L858R
mutant in type II pneumocytes under the control of doxycycline
(Ji et al, 2006; Politi et al, 2006). Expression of either EGFR mutant
leads to the development of adenocarcinoma similar to human
bronchioloalveolar cell carcinoma and withdrawal of doxycycline
to reduce expression of transgene or erlotinib treatment resulted in
tumour regression. Thus, these experiments showed that persistent
EGFR signalling is required for tumour maintenance in human
lung adenocarcinomas expressing EGFR mutants.
EGFR GENE COPY NUMBER
Cappuzzo et al (2004) reported that increase in EGFR gene copy
number, as determined by fluorescence in situ hybridisation, is
more predictive of the patient survival after gefitinib treatment
than EGFR mutations (Cappuzzo et al, 2005a). However, this
report does not necessarily refute the role of EGFR mutations as a
predictive factor because EGFR mutations only failed to signifi-
cantly affect overall survival (P¼0.09), whereas EGFR mutations
were predictive of response rate and time to progression
(Cappuzzo et al, 2005a). However, it should be noted that their
definition of increased gene copy number included both gene
amplification and high polysomy (more than 40% of tumour cells
have more than four copies of the EGFR gene). It is biologically
unclear whether high polysomy indicates the activation of the
EGFR gene, resulting in effects similar to those caused by gene
amplification. Tsao et al (2005) reported that increased EGFR gene
copy number is most predictive of a longer survival in patients
who received erlotinib in a phase III clinical trial (BR.21) that
compared erlotinib with best supportive care. They concluded that
the detection of EGFR mutations is not necessary in selecting
patients who will benefit from erlotinib therapy (Tsao et al, 2005).
Recently it was reported that EGFR gene copy number but not
gene mutation was the predictor of clinical benefit from gefitinib
in ISEL, a similar randomised trial comparing gefitinib with
placebo (Hirsch et al, 2006).
However, many investigators refute this point. Han et al (2006)
recently reported that EGFR mutation and high gene copy number
were associated with better objective response in univariate
analysis. Only gefitinib-sensitive EGFR mutation was indepen-
dently predictive of both response and survival in multivariate
analysis. Furthermore, Tsao et al (2005) report that 53% of the
EGFR mutations they found were novel variant mutations, of
which 92% were C/G-T/A or A/T-G/C transitions. Marchetti
et al (2006) suggested that at least some of these mutations could
be artifactual if Tsao et al (2005) used small amount of DNA from
paraffin-embedded tissues. Tsao et al(2005) responded to this
comment by stating that even when the mutation analysis was
confined to patients with exon 19 deletion and L858R, overall
results did not change, confirming no association of response
and survival for mutations in the BR.21 trial (Tsao et al, 2005). In
general, tumours with EGFR mutations tend to have gene
amplification. Mutation and amplification are probably both
important in determining TKI sensitivity. To resolve this
controversy, both EGFR mutations and amplification should be
determined prospectively in future clinical trials. These results are
also summarised in Table 1.
OTHER MOLECULAR PARAMETERS
Ligands
Using cDNA microarray, increased expression of amphiregulin or
TGF-a, known to be the ligands for EGFR, is related with poor
response to gefitinib (Kakiuchi et al, 2004). Recently, it was
reported that heregulin, ligand for HER3, expression correlates
with gefitinib insensitivity (Zhou et al, 2006). The ADAMs (a
disintegrin and metalloproteases), zinc-dependent membrane-
associated proteases, control the cleavage of most EGF-related
ligands. Zhou et al (2006) also showed that ADAM17 protein is
upregulated in NSCLC and correlated with heregulin-mediated
HER3 activation, leading to gefitinib insensitivity
Receptors
In addition to EGFR gene copy numbers, Cappuzzo et al (2005c)
reported that increased HER2 gene copy number is associated with
response to gefitinib therapy in EGFR-mutated NSCLC. However,
the same group reported that genomic gain for HER3 is not a
marker for response or resistance to TKI therapy in advanced
NSCLC patients (Cappuzzo et al, 2005b). It is also reported that
cancer cells having HER2 mutations, present in a very small
fraction of NSCLC, are insensitive to EGFR-TKI, but remain
sensitive to HER2-targeted therapies (Wang et al, 2006).
Downstream molecules
Pao et al (2005b) first reported that lung cancers with KRAS
mutations are resistant to EGFR-TKIs. None of the nine tumours
with KRAS mutations responded to EGFR-TKIs (Pao et al, 2005b).
However, Miller et al (2006) showed that in their study of
adenocarcinoma with bronchioloalveolar cell feature treated with
erlotinib, some of the tumours with KRAS mutations showed
minor tumour shrinkage, although response rate of lung cancer
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Mutational status Copy number
Tumour response TTP OS Tumour response TTP OS
Mut Wt RR High Low RR
Investigator Source TKI N R NR R NR Mut Wt Mut Wt P Mut Wt P N Method R NR R NR High Low High Low P High Low P
Retrospective analyses of patients from a single institution
Paez Science 2004 G 9 5 0 0 4 100 0
Lynch NEJM 2004 G 16 8 0 1 7 100 13
Pao PNAS 2004 G 18 7 0 3 8 100 27
Pao PNAS 2004 E 17 5 0 2 10 100 17
Huang JCO 2004 G 16 7 1 2 6 88 25
Tokumo CCR 2005 G 21 8 1 2 10 89 17 25.1 14 0.15
Mitsudomi JCO 2005 G 50 24 5 2 19 83 10 NR 14 0.0053
Han JCO 2005 G 90 11 6 10 63 65 14 21.7 1.7 o0.001 30.5 6.6 o0.001
Kim CCR 2005 G 27 6 0 2 19 100 10 47.3 11.9 0.008
Cortes-Funes Ann Oncol 2005 G 78 6 4 6 62 60 9 13 4.9 0.02
Cappuzzo NEJM 2005 G 89 8 7 4 70 53 5 9.9 2.7 0 20.8 8.5 0.09 102 FISH 12 21 2 67 36 3 9.0 2.5 o0.001 18.7 7.1 0.03
Chou CCR 2005 G 54 17 16 4 17 52 19 14.5
a 4
a 0.046
Taron CCR 2005 G 65 16 1 6 42 94 13 NR 9.9 0.001
Takano JCO 2005 G 66 32 7 3 24 82 11 12.6 1.7 o0.0001 20.4 6.9 0.0001 66 qPCR 21 8 14 23 72 38 9.4 26.0 0.038 0.49
Zhang Ann Oncol 2005 G 30 8 4 1 17 67 6 NR 7 0.0022
Mu CCR 2005 G 22 7 3 0 12 70 0
Tomizawa CCR 2005 G 22 12 0 4 6 100 40
Han CCR 2006 G 66 qPCR 10 21 4 31 32 11 3.6 1.9 0.21 12.3 8.4 0.49
Retrospective analyses of patients enrolled in multiinstitutional clinical trials
Bell JCO 2005 G 80 6 7 6 61 46 9 5.5
a 1.9
a S 7.9
a 6.1
a NS 86 qPCR 2 5 12 67 29 15 5.5
a 2.0
a S 8.1
a 6.2
a NS
Tsao NEJM 2005 E 100 3 16 6 75 16 7 7.5
a 8.8
a NS 66 FISH 5 20 1 40 20 2 10.7
a 7.8
a S
Hirsch JCO 2006 G 132 6 10 3 113 38 3 Insufficient data
for survival analysis
222 FISH 11 56 5 150 16 3 4.5 2.4 8.3 4.3 S
Hirsch JCO 2005 G 55 FISH 5 14 4 32 26 11 9.0 4.0 0.072 NR 8.0 0.042
Prospective study for EGFR mutation as a predictor of tumour response
Paz-Ares ASCO 2006 E 38 31 7 82
Okamoto ASCO 2006 G 27 20 7 74
Sutani ASCO 2006 G 35 21 6 1 7 78 13
Morikawa ASCO 2006 G 47 21 13 2 11 62 15
Yoshida JTO 2007 G 21 19 2 90
Totals 1170 314 123 70 663 72 10 663 66 145 42 410 31 9
Abbreviations: E, erlotinib; EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridisation; G, gefitinib; Mut, mutation; N, number of patients; NR, non-responder; NS, not significant; OS, Overall survival; qPCR,
quantitative PCR; RR, response rate; TKI, tyrosine kinase inhibitor; TTP, time to progression; WT, wild-type; R, responder; S, significant.
aRead directly from graphs.
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Kwith KRAS mutations was zero by RECIST. Thus, it is not possible
to exclude patients with KRAS mutations from the list of patients
with potential clinical benefit from EGFR-TKI therapy.
AKT is phosphorylated on EGFR activation, transmitting signals
for cell survival. It is reported that patients with phospho AKT-
positive tumours had a better response rate, disease control rate,
and time to progression by gefitinib treatment (Cappuzzo et al,
2004). Expression of E-cadherin, a calcium-dependent adhesion
molecule, has been related to sensitivity to gefitinib (Witta et al,
2006). These lines of evidence clearly indicate that comprehensive
analyses of molecular biomarkers should be carried out in
conjunction with clinical trials of EGFR inhibitors.
RESISTANCE TO EGFR-TKI
In contrast to the inherent resistance to gefitinib such as that by
KRAS mutations described above, it is common for patients to
show progressive disease after presenting with an initial good
response. A secondary mutation resulting in threonine to
methionine at codon 790 (T790M) has been reported to be
responsible for the acquired resistance (Kobayashi et al, 2005;
Pao et al, 2005a). Crystal structure modelling has revealed that
position T790 is located in the ATP-binding pocket of the catalytic
region and appears to be critical for the binding of erlotinib and
gefitinib. Substitution of the threonine at this codon with a bulkier
residue, such as methionine, is thought to sterically hinder the
binding of these two drugs. We recently reported that out of 14
patients who developed acquired resistance after initial good
response, seven patients harboured additional T790M mutation
(Kosaka et al, 2006). However, we were not able to find novel
mutations related to this resistance, which is in good contrast with
resistance in imatinib treatment for chronic myeloid leukaemia
where more than 30 mutations of the ABL gene have been
reported. In tumours from patients not treated with TKI, T790M
appears to be rare, approximately 0.5% (Toyooka et al, 2005). The
possibility exists, however, that this second mutation might be
present at a low frequency at the time of diagnosis and that tumour
cells harbouring this mutation might be enriched over time during
treatment with gefitinib (Inukai et al, 2006).
TKIs AND CLINICAL TRIALS
The addition of TKIs (gefitinib or erlotinib) did not yield a survival
advantage over platinum doublet (carboplatin/paclitaxel or
cisplatin/gemcitabine) in four randomised trials (INTACT I, II
TALENT, and TRIBUTE). However, subgroup analysis of the
TRIBUTE trial showed that the addition of erlotinib to carboplatin
plus paclitaxel conferred an advantage in overall survival in
patients who were never-smokers (MST 22.5 months vs 10.1
months; P¼0.01) (Herbst et al, 2005).
In a randomised placebo-controlled trial to determine whether
erlotinib prolonged survival in patients with NSCLC after the
failure of chemotherapy (BR.21), erlotinib significantly prolonged
survival, with an MST of 6.7 months vs 4.7 months (hazard ratio
0.70; Po0.001) (Shepherd et al, 2005). In contrast, a similar
placebo-controlled randomised trial using gefitinib (ISEL trial)
failed to show an overall survival advantage in the gefitinib
treatment group (MST of 5.6 months vs 5.1 months; P¼0.087)
(Thatcher et al, 2005). However, gefitinib prolonged survival in
never-smokers (MST 8.9 months vs 6.1 months; P¼0.012) as well
as in Asian patients (MST 9.5 months vs 5.5 months; P¼0.010) in
preplanned subset analyses (Thatcher et al, 2005). Following these
results, the US Food and Drug Administration limits the indication
of gefitinib to cancer patients who are currently benefiting or have
previously benefited from gefitinib treatment or are enrolled in
clinical trials as of June 2005.
As has been described, EGFR-TKIs are not universally effective
for lung cancer, but these drugs are effective in patients who have
particular clinical or biological characteristics, for example, Asian,
nonsmoking female patients with adenocarcinomas with EGFR
mutations. The different outcomes of the BR.21 and ISEL trials are
at least partly attributable to differences in the degree of dilution in
the two trials of patients with the above-mentioned characteristics
by those without such characteristics. Therefore, patients who
would benefit from EGFR-TKI therapy should be concentrated in
future clinical trials. Smoking history and EGFR mutations are
good predictors of response in patients treated with EGFR-TKIs.
Which of these two markers should we use in future clinical trials?
In our exploratory subset analysis, tumour response was observed
in 16 out of 19 patients with both EGFR mutations and no smoking
history (Mitsudomi et al, 2005). Whereas a response was seen in
one out of six never-smokers without EGFR mutations, a response
was seen in eight out of 10 smokers with EGFR mutations
(Mitsudomi et al, 2005). Therefore, our limited experience
indicates that EGFR mutations may be superior to smoking
history in the selection of patients who would benefit from TKI
treatment and that smoking history is only a surrogate marker of
EGFR mutation. Obviously, the detection of EGFR mutations
requires laborious laboratory work. Hence, smoking history can
be used in contexts in which EGFR gene testing is not readily
available. In April 2004, IPASS (iressa pan-Asian study) was
started. This is an open-labelled randomised phase III study
comparing gefitinib monotherapy with cariboplatin/paclitaxel for
previously untreated patients with adenocaricnoma who are never-
or light smokers. The West Japan Thoracic Oncology Group,
launched a phase III clinical trial comparing gefitinib mono-
therapy with cisplatin plus docetaxel in lung-cancer patients with
EGFR. Primary end point is progression-free survival, to avoid
confounding by possible crossover between two arms and the
sample size is 200 patients with EGFR mutations. We also limit
our mutation search to deletions in exon 19 and L858R, because it
would be less laborious and these two are most reliable predictor
for response or survival. In this way, the survival benefit of EGFR-
TKIs, especially gefitinib, should be demonstrated in future clinical
trials in a defined subset of patients with lung cancer.
LIFE-THREATENING INTERSTITIAL LUNG DISEASE
In Japan, soon after the introduction of gefitinib, life-threatening
interstitial lung disease or acute lung injury attributable to
gefitinib became apparent. Recently published retrospective survey
of 1976 Japanese patients showed prevalence and morality of ILD
was 3.5 and 1.6%, respectively (Ando et al, 2006). Gefitinib-
induced ILD was significantly associated with male sex, a history of
smoking, and coincidence of interstitial pneumonitis (odds ratios
3.10, 4.79, and 2.89, respectively) (Ando et al, 2006). Although it is
not very clear whether the high incidence of ILD is common in
East Asian countries, Chiu et al (2005) reported from Taiwan that
geftinib-related interstitial pneumonia was clinically diagnosed in
four cases (5.8%) in 69 patients. Biomarkers including genetic
polymorphisms that predict occurrence of ILD should be actively
sought. The incidence of ILD by erlotinib appears similar in Japan.
In a recent phase II trial of erlotinib conducted in Japan, possible
ILD-like events were reported in four of 60 evaluable patients
(6.7%)(Tamura et al, 2006), whereas ILD was reported in three of
485 in BR. 21 (Shepherd et al, 2004).
CONCLUSIONS
Considering great complexity and redundancy of EGFR pathway, it
is natural to assume that one cannot expect a sole determinant
of clinical benefit of EGFR-TKIs. Figure 1 summarises current
knowledge of molecular predictors for EGFR-TKI discussed above.
The development of EGFR-TKIs and the discovery of EGFR gene
mutations have provided a great opportunity for translation of
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lung cancer. However, we should continue our effort to search for
better biomarker(s) that is most clinically relevant. Particularly in
Japan, risk of ILD and potential benefit of EGFR-TKI therapy
should be well balanced.
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Figure 1 Potential molecular biomarkers to predict responsiveness for EGFR-TKI in EGFR signalling pathways. Sensitive and resistant markers are
indicated by grey and black boxes, respectively.
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